Start Date
January 31, 2013
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
Dasatinib
"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
Lead Sponsor
Brown University
OTHER